Abstract

BackgroundTherapeutic options in IgAN are still limited. The aim of this study is to explore the feasibility of using endothelial progenitor cell to treat IgAN in rat model.MethodsRat bone marrow mononuclear cells (BM-MNCs) obtained with density gradient centrifugation were cultured in vitro, and induced into endothelial progenitor cells (EPCs). EPCs were identified by surface marker CD34, CD133 and VEGFR2 (FLK-1) and by Dil-Ac-LDL/FITC-UEA-1 double staining. EPCs were labeled with PKH26 prior to transplantation. Rat model of IgAN was established by oral administration of bovine serum albumin together with lipopolysaccharide via the caudal vein and subcutaneous injection of CCL4. Kidney paraffin sections were stained by H&E and PAS. Immunofluorescence was used to assess IgA deposition in the glomeruli. Peritubular capillary (PTC) density was determined by CD31 staining. Monocyte chemoattrant protein-1 (MCP-1), hypoxia-inducible factor-1α (HIF-1α) and CD105 were also measured by immunohistochemistry, western blotting and real-time fluorescent quantitative PCR.ResultsThe transplanted BM-EPCs were successfully located in IgAN rat kidney. After transplantation, Urinary red blood cell, urine protein, BUN, Scr and IgA serum level were significantly decreased, so were the areas of glomerular extracellular matrix and the IgA deposition in the glomeruli. In addition, PTC density was elevated. And the expression levels of HIF-1α and MCP-1 were significantly down-regulated, while the expression of CD105 was up-regulated. All these changes were not observed in control groups.ConclusionThe BM-EPCs transplantation significantly decreases the expansion of glomerular extracellular matrix and the deposition of IgA in the glomeruli; lowers the expression of inflammatory factors; increases PTC density; improves ischemic-induced renal tissue hypoxia, all of which improves the renal function and slows the progress of IgA nephropathy.

Highlights

  • Therapeutic options in IgAN are still limited

  • Previous studies have shown that in IgAN patients, cell damage and apoptosis of renal microvascular endothelial cells and loss of Peritubular capillary (PTC) cause renal ischemia, hypoxia, activation of stromal cell, secretion of fibrosis cytokines, which leads to the upregulation of fibrosisrelated genes and accumulation of extracellular matrix (ECM) [2,3,4,5]

  • IgAN rats were found to show grey hair and slow-growing. 24-hour urine protein, Urinary red blood cell, blood urea nitrogen (BUN), serum creatinine (Scr) and IgA serum level were significantly elevated in IgAN rats

Read more

Summary

Introduction

The aim of this study is to explore the feasibility of using endothelial progenitor cell to treat IgAN in rat model. Glomerulosclerosis and interstitial fibrosis are irreversible pathological changes during the development of IgAN to ESRD. The focus of our research on how to delay the progress of renal fibrosis in IgAN patients. Previous studies have shown that in IgAN patients, cell damage and apoptosis of renal microvascular endothelial cells and loss of PTC cause renal ischemia, hypoxia, activation of stromal cell, secretion of fibrosis cytokines, which leads to the upregulation of fibrosisrelated genes and accumulation of extracellular matrix (ECM) [2,3,4,5]. The aim of our study is to investigate whether BM-EPCs transplantation will be an effective therapeutic mean for IgAN patients

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call